The Effect of Breastfeeding Education Using the Pecha Kucha Technique on Breastfeeding Self-Efficacy and Breastfeeding Success in the Early Postpartum Period: A Randomized Controlled Trial

June 13, 2026 updated by: YASEMİN AYDIN KARTAL, Saglik Bilimleri Universitesi
Breast milk is considered the most biologically appropriate source of nutrition, essential for the healthy growth and development of newborns. Thanks to its optimal nutrients, immunological factors, and growth regulators, it not only meets nutritional needs but also protects against infections, reducing neonatal morbidity and mortality rates. The Pecha Kucha presentation technique keeps presentations concise and dynamic, creating a fast-paced, light, and engaging experience. It minimizes distractions and maximizes engagement. Because there is no text to read in the Pecha Kucha technique, presenters are required to be more prepared and strive to create a coherent narrative, resulting in a flawless narrative. Thus, the aim is to ensure the success and effectiveness of breastfeeding education with this technique, and ultimately, to promote breastfeeding education using the Pecha Kucha technique to healthcare professionals. The population of this randomized, controlled experimental study consists of primiparous postpartum women who gave birth in the Obstetrics Department of the Physical Therapy Annex Building of the Gaziosmanpaşa Training and Research Hospital at the University of Health Sciences. A power analysis was conducted using the G*Power package program, Version 3.1.9.4, to determine the sample size of the study. Because no similar research was found in the literature, Cohen's medium effect size was chosen as the effect size, anticipating that tests assessing the difference between two independent groups would be used when examining the differences in variables between the control and intervention groups. Accordingly, with 64 participants in the control group and 64 in the intervention group, a power of 80% was calculated at a significance level of 0.5 (medium) effect size and 0.05, and a minimum sample size of 128 was determined. The study, planned using an experimental design, is planned to be conducted on two groups: an intervention and a control group. Within the scope of the study, pretest data will be collected by administering the Breastfeeding Self-Efficacy Scale and the LATCH Breastfeeding Diagnostic and Assessment Scale, along with an introductory information form, to postpartum women who agree to participate in the study.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
128

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • - Being primiparous
  • Having a full-term, singleton birth
  • Having a healthy newborn
  • Having a spontaneous vaginal birth

Exclusion Criteria:

  • Being multiparous (having given birth more than once)
  • Having given birth preterm or postterm
  • Having a mother or newborn with health problems
  • Having had a multiple pregnancy
  • Having had a cesarean section

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: intervention group
Mothers in the intervention group will receive breastfeeding training using the Pecha Kucha presentation technique at the first hour postpartum
Other: pecha kucha
Training will be provided using training material consisting of 20 slides, each lasting 20 seconds, prepared using the 'Pecha Kucha' technique, for a total duration of 6 minutes and 20 seconds.
No Intervention: control group
Standard breastfeeding education, as part of the routine postpartum care practices of the Ministry of Health, will be given to the puerperal women in the control group at the first hour postpartum.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
introductory information form
Time Frame: 10 minitus
This form, created by researchers based on literature, includes questions about the participants' age, high school graduation, their self-sufficiency against disasters, etc.
10 minitus
Breastfeeding Self-Efficacy Scale
Time Frame: 10 minutes
The Breastfeeding Self-Efficacy Scale was developed by the National Institutes of Health (NIH) to assess mothers' breastfeeding self-efficacy levels. The initial form consisted of 33 items. In 2003, the scale was shortened to a 14-item version.Dennis recommends using the short form. The Breastfeeding Self-Efficacy Short Form Scale is a 5-point Likert-type scale (1 = Not at all confident and 5 = Always confident). The lowest possible score is 14, and the highest is 70. As the score increases, breastfeeding self-efficacy also increases. The validity and reliability of the scale in Turkey were conducted by Aluş Tokat, Okumus, and Dennis (2010). The scale is a 5-point Likert-type scale, with scores ranging from Not at all confident (1 point) to Always confident (5 points). The minimum possible score is 14, and the maximum score is 70. There is no cut-off point for the scale. A higher score indicates higher breastfeeding self-efficacy. The Cronbach's alpha for the scale was found to be0.87
10 minutes
Latch Breastfeeding Diagnostic and Assessment Scale
Time Frame: 10 minutes
The LATCH Breastfeeding Diagnostic Measurement Tool was developed by Jensen and colleagues (1994). LATCH is a diagnostic tool created by simulating the Apgar scoring system in terms of its scoring method. It is a quick and easy scale to evaluate (Jensen, Wallace 1994). The Turkish validation of the tool was conducted by Demirhan in 1997, Koyun in 2001, and Yenal and Okumuş in 2003, and it was recommended as a reliable tool. The lowest score obtained from the scale is 0, and the highest is 10. A higher score indicates breastfeeding success. The Cronbach's alpha value of the LATCH Breastfeeding Diagnostic Measurement Tool was found to be 0.95 by Yenal and Okumuş.
10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Saglik Bilimleri Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 13, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 18, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SBU-AYDINKARTAL-KAYADUMAN

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pecha Kuka

Clinical Trials on pecha kucha

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings